Our Partners & Pipeline

AI-Enabled Small & Medium-Size Molecule Drugs

We deploy our AI in our labs and with large pharma partners to develop highly potent and selective drugs, for chemically complex targets, to treat severe diseases. Wet labs close the loop for model training, prediction, and validation.
01

Our Partners

We partner with industry leaders to amplify the impact of our platform for drug discovery

By combining GEMS with our partners' R&D prowess, we aim to further accelerate impact for patients.

Incyte

In 2025, Genesis partnered with Incyte to leverage GEMS for Incyte-selected targets. Genesis received a $30 million upfront payment to collaborate on 2 initial targets.
Multi-target collaboration
Started 2025

Gilead

In 2024, Genesis partnered with Gilead to deploy GEMS against multiple hard-to-drug targets. Genesis received $35 million in upfront payment to collaborate on 3 initial targets.
Multi-target collaboration
Started 2024
02

AI + Wet Lab Flywheel

GEMS AI drives molecular design

wet lab experimental ground truth

stronger AI

Genesis has a team of forward deployed engineers and drug hunters who work in unison on our partnerships. These same researchers stress test and strengthen GEMS and its predictions on every partnered and internal program. The combination of expertise, technology, and data together sustain a flywheel that is solving the most critical problems in our field.
03

ONCOLOGY PIPELINE

Better options where current therapies fall short.

Using GEMS to generate and optimize first- or best-in-class small molecules for difficult biological targets, which offer potential to advance the treatment of difficult cancers.
Best-in-class pan-mutant PIK3CA
PIK3CA is a common oncogenic driver in breast and colorectal cancers. Genesis is approaching development candidate nomination for highly potent and selective pan-mutant allosteric inhibitors of PIK3CA.
Breast Cancer
Colorectal Cancer
First-in-class cell-death promoter
Genesis is generating small molecules to inhibit an important anti-apoptotic regulator of the extrinsic cell death pathway, which could prevent evasion of apoptosis in cancer cells with this dependency.
04

IMMUNOLOGY PIPELINE

Pursuing autoimmune targets that small molecules haven't reached.

Using GEMS to generate and optimize first-in-class small molecules for well-validated targets, as well as novel immunology targets.

Validated immunology

First-in-class small molecule
Many targets for autoimmune disorders have proven efficacy from approved or clinical stage biologics, but have yet to be drugged with small molecules. Genesis has multiple programs generating small molecules to inhibit such well-validated targets, to offer oral treatment options to patients in need.

Novel immunology

First-in-class autoimmune disorder
Genesis is developing small molecule inhibitors targeting a protein central to several inflammatory signaling pathways, aiming to meet the unmet needs of patients with autoimmune diseases
First-in-class small molecule
Many targets for autoimmune disorders have proven efficacy from approved or clinical stage biologics, but have yet to be drugged with small molecules. Genesis has multiple programs generating small molecules to inhibit such well-validated targets, to offer oral treatment options to patients in need.
First-in-class autoimmune disorder
Genesis is developing small molecule inhibitors targeting proteins central to several inflammatory signaling pathways, aiming to address the unmet needs of patients with autoimmune diseases

Our People

Deploying GEMS AI and Powering the Pharma Industry

At Genesis, leading AI researchers team with world-class drug hunters to develop and deploy GEMS for our partnered and wholly owned pipeline of discovery programs. Our AI research is based in the Bay Area and New York City, with our wet lab in San Diego. Our team seamlessly works across disciplines internally and as forward-deployed engineers (FDEs) and scientists
Our Scientific Careers

In The News

December 2, 2025

Genesis Molecular AI Appoints Sergey Edunov as Senior Vice President of Foundation Models, Further Strengthening Leadership in Machine Learning

October 28, 2025

Introducing Pearl: The Next Generation Foundation Model for Drug Discovery

Genesis Molecular AI ©2026